The latest price target for (:CMAX) was reported by UBS on April 1, 2024. The analyst firm set a price target for $6.40 expecting CMAX to fall to within 12 months (a possible NaN% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for (:CMAX) was provided by UBS, and maintained their neutral rating.

There is no last upgrade for

The last downgrade for happened on November 17, 2023 when UBS changed their price target from $5 to $1 for .

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of , and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for was filed on April 1, 2024 so you should expect the next rating to be made available sometime around April 1, 2025.

While ratings are subjective and will change, the latest (CMAX) rating was a maintained with a price target of $7.00 to $6.40. The current price (CMAX) is trading at is $undefined, which is out of the analyst’s predicted range.